Immunovant, Inc.
IMVT
$15.08
$0.191.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 84.45M | 77.24M | 71.88M | 65.32M | 60.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 471.09M | 438.15M | 405.21M | 352.46M | 298.51M |
| Operating Income | -471.09M | -438.15M | -405.21M | -352.46M | -298.51M |
| Income Before Tax | -445.58M | -412.95M | -382.17M | -322.73M | -271.89M |
| Income Tax Expenses | 1.73M | 890.00K | 539.00K | 279.00K | 655.00K |
| Earnings from Continuing Operations | -447.30 | -413.84 | -382.71 | -323.01 | -272.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -447.30M | -413.84M | -382.71M | -323.01M | -272.55M |
| EBIT | -471.09M | -438.15M | -405.21M | -352.46M | -298.51M |
| EBITDA | -470.69M | -437.77M | -404.87M | -352.17M | -298.26M |
| EPS Basic | -2.85 | -2.74 | -2.62 | -2.22 | -1.92 |
| Normalized Basic EPS | -1.77 | -1.71 | -1.63 | -1.38 | -1.20 |
| EPS Diluted | -2.85 | -2.74 | -2.62 | -2.22 | -1.92 |
| Normalized Diluted EPS | -1.77 | -1.71 | -1.63 | -1.38 | -1.20 |
| Average Basic Shares Outstanding | 631.00M | 606.21M | 584.83M | 582.43M | 567.12M |
| Average Diluted Shares Outstanding | 631.00M | 606.21M | 584.83M | 582.43M | 567.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |